Orca Bio.png
Orca Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 06, 2021 08:00 ET | Orca Bio
MENLO PARK, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Orca Bio, a clinical-stage biotechnology company developing high-precision cell therapies for patients with blood diseases, today announced that...
Orca Bio.png
First Clinical Data from Ongoing Orca-T Trial Shows Significantly Improved 12-Month Graft Versus Host Disease (GvHD)-Free and Relapse-Free Survival (GRFS) in Blood Cancer Patients Receiving a Hematopoietic Stem Cell Transplant (HSCT)
December 06, 2020 12:30 ET | Orca Bio
— Early multi-center results indicate that Orca-T, a novel approach to HSCT, improves time-to-engraftment, markedly reduces the incidence and severity of GvHD, and significantly improved GRFS at 1...
Orca Bio.png
Orca Bio Announces Oral Presentation of Orca-T Clinical Data at the 62nd American Society of Hematology (ASH) Annual Meeting
November 04, 2020 12:51 ET | Orca Bio
-- Data provide insights into manufacturing efficiency, logistics and early clinical outcomes of Orca-T for patients with blood cancers -- MENLO PARK, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Orca...
Orca Bio.png
Orca Bio Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Orca-T
October 14, 2020 07:30 ET | Orca Bio
MENLO PARK, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Orca Bio, a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted RMAT designation...
Orca Bio.png
Orca Bio and Lyell Immunopharma Announce Research Partnership
September 02, 2020 07:30 ET | Orca Bio
— The partnership promotes complementary scientific technologies to develop next generation cell-based therapies for patients with solid cancers — MENLO PARK, Calif. and SOUTH SAN FRANCISCO,...
Orca Bio.png
Orca Bio Emerges With Nearly $300 Million to Transform Allogeneic Cell Therapy
June 17, 2020 07:00 ET | Orca Bio
Company aims to safely and effectively regenerate a healthy blood and immune system for patients with hematological malignancies, genetic diseases and autoimmune disorders High precision cell...